Here, we provide an overview of the c-level moves that have taken place within the industry between April and June 2025.

The ABPI has confirmed that Russell Abberley is the latest President-elect. Abberley, Vice President and General Manager of Amgen UK and Ireland, formally took up the Presidency on 13 May for a period of two years.

Nucleome Therapeutics has appointed Bhavna Hunjan as Chief Business Officer, who leaves a role as Chief Business Officer and Board Director at C4X Discovery.

iOnctura has bolstered its leadership team with the appointments of Steven Sciuto as Chief Financial Officer and Michelle Tsai as Chief Operating Officer.

Commit Biologics has formed a new board which will be co-chaired by antibody expert Dr Janine Schuurman, and Commit’s CEO Mikkel Wandahl Pedersen. They are being joined by Dr Paul Parren, Professor of Molecular Immunology, former Genmab SVP and biotech entrepreneur; Dr Gavin Thurston, former Regeneron SVP of Oncology Research; Dr Susan Kalled, esteemed immunologist who has previously worked as CSO at both Dianthus Therapeutics and Compass Therapeutics; and Dr Esper Boel, molecular biologist and previously CTO at Symphogen and Corporate Vice President and Head of Biotechnology at Novo Nordisk.

Asgard Therapeutics has strengthened its Board of Directors and Advisory Board with the appointments of Dr Cristina Csimma as an independent member of its Board of Directors, and Professor Ignacio Melero and Professor Brian Brown to its Clinical and Scientific Advisory Board.

STORM Therapeutics has appointed Atif Abbas as Chief Medical Officer, who leaves his role as VP at Servier Pharmaceuticals, having held multiple roles in clinical development at Merck, Abbvie, Astellas and Boehringer Ingelheim.

Augustine Therapeutics has hired Dr Rie Schultz Hansen as Chief Scientific Officer, who leaves the same role at Aelin Therapeutics with 20 years’ experience in drug discovery and early-stage drug development.

Closed Loop Medicine has promoted Kate Woolland to Chief Executive Officer, having previously served as the company’s Chief Operating Officer.

Slingshot Therapeutics strengthens its team through the appointment of Ed Savory as Head of Chemistry, who leaves his role as Senior Vice President, Drug Discovery at BenevolentAI.

Shift Bioscience has appointed Lord David Prior as Chair of the Board, previously Chairman of NHS England and member of the UK Life Sciences Council, as well as Sir Tony Kouzarides, Co-founder and Director, Milner Therapeutics Institute, and Professor of Cancer Biology, Gurdon Institute, as Scientific Advisor.

VERAXA Biotech welcomes Rick Austin as Chief Scientific Officer, who previously served as Vice President, Research at Harpoon Therapeutics.

Bora Pharmaceuticals has appointed Jean-Baptiste Agnus as Chief Commercial Officer, who leaves a role at KBI Biopharma, where he led global business development.

Trogenix has made additions to its Scientific Advisory Board with the appointment of Professor Nada Jabado and Professor Burkhard Becher.

Jumo Health has made Brittany Erana the Chief Executive Officer to lead next phase of growth for the company. Prior to joining Jumo, Erana served as General Manager at PPD.

hVIVO’s newest Independent Non-Executive Director has been appointed: Tracey James, who will be Chair of the Audit Committee, and a member of the Remuneration and Nominations Committees.

Sapio Sciences has promoted Gordon McCall to Chief Operating Officer, following his successful track record as Chief Financial Officer.

Swiss Rockets has made updates to its leadership team with key appointments. Dr Carlo Durrer joins as Chief Quality Officer, Dr Patrick Schnider assumes the role of Head of Research & Development, and Dr Claudia Bernoulli joins as Head of Quality Assurance.

PhoreMost’s most recent appointments bring commercial and leadership expertise to its board, with Barbara Duncan as Chair, and Stephen Dilly as Non-Executive Director.

Mammoth Biosciences has placed genetic medicines ‘veteran’ Bob D Brown on its Board of Directors, who brings expertise in nucleic acid drug development to the role.

Essential Pharma brought Duncan Ferguson on as Vice President, Commercial, in order to strengthen its leadership team. Previously, Ferguson served as Head of Partner Markets at Jazz Pharmaceuticals.

Supreme Group has made space for Dr Ramon Felciano on its Board to guide AI innovation in life sciences marketing.

MitoRx Therapeutics has moved to its next development stage with the appointment of Xavier Jacq as Chief Scientific Officer. Jacq previously held scientific leadership positions at Almac and Mission Therapeutics, and project leadership positions at Kudos and Sanofi.

Astoriom has hired Ryan Smith as Global Head of Sales. Most recently, Smith led the global sales team at Azenta Life Sciences (formerly Brooks Life Sciences).

Nuclera welcomes Seth Benson as Chief Financial Officer. Benson’s appointment comes after Nuclera strengthened its leadership team with three key appointments in October 2024.

Syncell has promoted Nikhil Rao to the role of Chief Commercial Officer, following his success as Senior Vice President of Commercial.